Haemonetics (HAE) Depreciation & Amortization (CF) (2009 - 2026)

Haemonetics' Depreciation & Amortization (CF) history runs 18 years deep, the most recent figure standing at $27.3 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 3.15% year-over-year to $27.3 million; the TTM figure through Mar 2026 stood at $111.7 million (down 3.35% YoY), while the FY2026 annual figure was $111.7 million, down 3.35% from the prior year.
• Depreciation & Amortization (CF) was $27.3 million for Q1 2026 at Haemonetics, roughly flat from $27.4 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $29.2 million in Q3 2024 to a low of $22.4 million in Q3 2022.
• Historically, Depreciation & Amortization (CF) has averaged $25.9 million across 5 years, with a median of $26.1 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) retreated 10.33% in 2022, then advanced 26.96% in 2024.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $23.6 million in 2022, then fell by 0.17% to $23.5 million in 2023, then gained by 23.35% to $29.0 million in 2024, then fell by 5.65% to $27.4 million in 2025, then retreated by 0.24% to $27.3 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $27.3 million (Q1 2026), $27.4 million (Q4 2025), and $28.3 million (Q3 2025), per Business Quant data.